Preparation of RGD-modified curcumin and doxorubicin co-loaded liposomes and assessment of their anti-colon cancer activity in vitro
CHEN Shihong
LIU Zuhao
WANG Kexing
MENG Yan
CHANG Cong
Abstract：Objective To prepare anti-tumor liposomes[cRGD-(C+D/LP)]co-loaded with targeted doxorubicin(DOX)and curcumin inclusion complex(CUR-CD),and to conduct comprehensive evaluation to assess its quality and anti-colon cancer activity in vitro.Methods CUR-CD was prepared through freeze-drying,followed by the preparation of cRGD-(C+D/LPs)using inclusion complex liposomes(LPs)technology.Infrared spectroscopy and X-ray diffraction were used for structural characterization of CUR-CD.The physical and chemical properties of the targeted LPs were assessed through transmission electron microscopy,particle size and zeta potential analysis,as well as high-performance liquid chromatography.Flow cytometry,MTT,and confocal laser scanning microscopy were used to investigate the endocytic pathway of cRGD-(C+D/LPs)and its efficacy against colon cancer cells.Results The prepared cRGD-(C+D/LPs)was a spherical vesicle with an average diameter of 379.5 nm that predominantly engaged in cellular internalization through the receptor-mediated endocytosis pathway.In comparison to free drugs and conventional LPs,cRGD-(C+D/LPs)accumulated significantly in tumor cells(P＜0.01).Moreover,the sensitizing impact of CUR enhanced the therapeutic efficacy of cRGD-(C+D/LPs)by impeding cell viability more effectively.Conclusion The combined strategy of dual-drug co-delivery and RGD-mediated targeting in cRGD-(C+D/LPs)underscores its potential as an advanced therapeutic approach for cancer treatment.
Keywords：curcumininclusion complexcyclic arginine-glycine-aspartateliposomemultidrug resistance
Publication Date：2024-05-28
Online Publishing Date：2026-08-26(First online date of this platform, not the publication date of the document)
Pages：8( 549-556 )